KINAZE in English translation

• kinase
• kinases

Examples of using Kinaze in Croatian and their translations into English

Ustanovljeno je da je razred inhibitora tirozin kinaze jak inhibitor CYP1A1, među kojima su erlotinib
The class of tyrosine kinase inhibitors was identified as potent inhibitors of CYP1A1,

Kabozantinib je mala molekula koja inhibira različite receptorske tirozin kinaze(RTK) povezane s rastom tumora
Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases(RTKs) implicated in tumour growth

Najčešće nuspojave bile su povišenje kreatin kinaze u krvi 3. ili 4. stupnja(6,8%),
The most common adverse reactions were grade 3 or 4 blood creatine kinase elevations(6.8%), fatigue(4.4%),

Suntinib inhibira višestruke receptorske tirozin kinaze(RTK) koje imaju ulogu u rastu tumora,
Sunitinib inhibits multiple receptor tyrosine kinases(RTKs) that are implicated in tumour growth,

Crizotinibni prašak je agens protiv raka koji djeluje kao anaplastični inhibitor limfoma kinaze i nedavno je odobren za liječenje karcinoma pluća ne-malih stanica.
Crizotinib powder is an anti-cancer agent acting as anaplastic lymphoma kinase inhibitor and recently approved for treatment of non-small cell lung carcinoma.

dabrafenib inhibiraju dvije kinaze u tom putu, MEK
dabrafenib inhibit two kinases in this pathway, MEK

dogodili su se u bolesnika koji su kronični nositelji HBV-a nakon što su primili inhibitore BCR-ABL tirozin kinaze TKI.
have occurred in patients who are chronic carriers of HBV after they received BCR-ABL tyrosine kinase inhibitors TKIs.

dabrafenib inhibiraju dvije kinaze u ovom putu, MEK
dabrafenib inhibit two kinases in this pathway, MEK

AZD-9291 prašak bio je vrlo aktivan u bolesnika s rakom pluća s EGFR T790M mutacijom koja je imala napredovanje bolesti tijekom prethodne terapije s inhibitorima EGFR tirozin kinaze.
AZD-9291 powder was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors.

nazvane kinaze, koji uzrokuju stanica koja se uzgaja
called kinases, to cause the cell to grown

u onih koji imaju mutirani receptor c-kit tirozin kinaze.
which express the mutated c-kit tyrosine kinase receptor.

ALK i ROS1 ubrajaju se u obitelj proteina naziva receptorske tirozin kinaze(RTK-ovi) koji su uključeni u rast stanica.
ALK and ROS1 belong to a family of proteins called receptor tyrosine kinases(RTKs), which are involved in the growth of cells.

u onih s izraženom mutacijom receptora c-kit tirozin kinaze.
which express the mutated c-kit tyrosine kinase receptor.

potom fosforilira u stanici pomoću deoksigvanozin kinaze i deoksicitidin kinaze u svoj 5'-monofosfatni metabolit.
then phosphorylated intracellularly by deoxyguanosine kinase and deoxycytidine kinase to its 5'-monophosphate metabolite.

Pretklinički podaci dobiveni u biokemijskim ispitivanjima pokazali su da dabrafenib inhibira BRAF kinaze s aktiviranom mutacijom kodona 600 tablica 5.
Preclinical data generated in biochemical assays demonstrated that dabrafenib inhibits BRAF kinases with activating codon 600 mutations Table 5.

Neklinički podaci dobiveni u biokemijskim testovima pokazali su da vemurafenib može snažno inhibirati BRAF kinaze s aktivirajućim mutacijama kodona 600 Tablica 6.
Preclinical data generated in biochemical assays demonstrated that vemurafenib can potently inhibit BRAF kinases with activating codon 600 mutations table 6.

daljnju apoptozu u staničnim linijama tumora koje izražavaju aktivirajuće mutacije u RTK-u razgrađene kinaze, c-Kit-u.
subsequent apoptosis in tumour cell lines expressing activating mutations in the split kinase RTK, c-Kit.

djeluje blokirajući skupine enzima poznatih kao Janus kinaze(JAK-ovi) koji su uključeni u stvaranje
works by blocking a group of enzymes known as Janus kinases(JAKs), which are involved in the production

Inhibicijom BCR-ABL tirozin kinaze ova skupina lijekova utječe na stanične funkcije u tumorskim stanicama u nekoliko različitih zloćudnih bolesti.
This group of medicinal products affects cell functions in cancer cells in several malignant diseases by inhibiting BCR-ABL tyrosine kinase.

Ako su početne vrijednosti kreatin kinaze značajno povišene(>
If Creatine Kinase levels are significantly elevated at baseline(>